Published in Mol Biochem Parasitol on May 08, 2012
Genetic manipulation in Δku80 strains for functional genomic analysis of Toxoplasma gondii. J Vis Exp (2013) 0.84
Isoprenoid metabolism in apicomplexan parasites. Curr Clin Microbiol Rep (2014) 0.83
Babesia bovis dihydroorotate dehydrogenase (BboDHODH) is a novel molecular target of drug for bovine babesiosis. J Vet Med Sci (2013) 0.75
Pyrimidine Pathway-Dependent and -Independent Functions of the Toxoplasma gondii Mitochondrial Dihydroorotate Dehydrogenase. Infect Immun (2016) 0.75
Pyrimidine Metabolism in Schistosomes: A comparison with Other Parasites and the Search for Potential Chemotherapeutic Targets. Comp Biochem Physiol B Biochem Mol Biol (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res (2003) 25.86
Toxoplasmosis. Lancet (2004) 13.96
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
Recombination-mediated PCR-directed plasmid construction in vivo in yeast. Nucleic Acids Res (1997) 5.03
Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. J Biol Chem (1996) 4.06
Crystal structure of mitochondrial respiratory membrane protein complex II. Cell (2005) 3.44
Toxoplasmosis: A history of clinical observations. Int J Parasitol (2009) 3.39
Tagging of endogenous genes in a Toxoplasma gondii strain lacking Ku80. Eukaryot Cell (2009) 3.32
Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature (2007) 3.08
De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature (2002) 3.04
Gene replacement in Toxoplasma gondii with chloramphenicol acetyltransferase as selectable marker. Science (1993) 2.98
Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis (2008) 2.73
High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrob Agents Chemother (2003) 2.62
Pyrimidine and purine biosynthesis and degradation in plants. Annu Rev Plant Biol (2006) 2.48
Efficient gene replacements in Toxoplasma gondii strains deficient for nonhomologous end joining. Eukaryot Cell (2009) 2.41
Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. EMBO J (2003) 2.26
Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion. Infect Immun (1994) 2.26
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure (2000) 1.98
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med (1987) 1.89
Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem (2004) 1.86
Insertional mutagenesis and marker rescue in a protozoan parasite: cloning of the uracil phosphoribosyltransferase locus from Toxoplasma gondii. Proc Natl Acad Sci U S A (1995) 1.79
High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem (2005) 1.73
Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem (2008) 1.67
Toxoplasma gondii: the enzymic defect of a mutant resistant to 5-fluorodeoxyuridine. Exp Parasitol (1978) 1.56
Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. Int J Parasitol (1995) 1.50
Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets (2010) 1.44
Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. Eukaryot Cell (2011) 1.40
Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem (2008) 1.34
Purines and pyrimidines in malarial parasites. Blood Cells (1990) 1.33
Characterization of the isoprenoid chain of coenzyme Q in Plasmodium falciparum. FEMS Microbiol Lett (2002) 1.30
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Host cell egress and invasion induce marked relocations of glycolytic enzymes in Toxoplasma gondii tachyzoites. PLoS Pathog (2008) 1.25
Yeast dihydroorotate dehydrogenase as a new selectable marker for Plasmodium falciparum transfection. Mol Biochem Parasitol (2011) 1.24
The crystal structure of the flavin containing enzyme dihydroorotate dehydrogenase A from Lactococcus lactis. Structure (1997) 1.22
E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure (2002) 1.22
Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem (2003) 1.21
Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr D Biol Crystallogr (2006) 1.15
Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets (2007) 1.14
A thioredoxin family protein of the apicoplast periphery identifies abundant candidate transport vesicles in Toxoplasma gondii. Eukaryot Cell (2008) 1.10
Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun (2010) 1.08
The origin of dihydroorotate dehydrogenase genes of kinetoplastids, with special reference to their biological significance and adaptation to anaerobic, parasitic conditions. J Mol Evol (2005) 1.06
Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur J Biochem (1996) 1.06
Dual binding mode of a novel series of DHODH inhibitors. J Med Chem (2006) 1.04
Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci (2004) 1.04
Structure of dihydroorotate dehydrogenase B: electron transfer between two flavin groups bridged by an iron-sulphur cluster. Structure (2000) 1.02
Respiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondii. J Biol Chem (1998) 1.01
Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase. Eur J Biochem (2000) 1.01
Phosphatidylinositol 3-monophosphate is involved in toxoplasma apicoplast biogenesis. PLoS Pathog (2011) 0.99
Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol (1998) 0.96
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem (2007) 0.95
Identification, molecular cloning and functional characterization of an octaprenyl pyrophosphate synthase in intra-erythrocytic stages of Plasmodium falciparum. Biochem J (2005) 0.94
Purification and characterization of dihydroorotate dehydrogenase A from Lactococcus lactis, crystallization and preliminary X-ray diffraction studies of the enzyme. Protein Sci (1996) 0.93
Growth-dependent regulation of mammalian pyrimidine biosynthesis by the protein kinase A and MAPK signaling cascades. J Biol Chem (2002) 0.93
Detection of ubiquinone in parasitic and free-living protozoa, including species devoid of mitochondria. Mol Biochem Parasitol (1994) 0.92
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem (2009) 0.92
Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs (2003) 0.91
Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii. Eukaryot Cell (2009) 0.91
The single mitochondrion of tachyzoites of Toxoplasma gondii. J Struct Biol (2000) 0.91
Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Eur J Biochem (2001) 0.89
A graphical method for determining inhibition parameters for partial and complete inhibitors. Biochem J (1987) 0.89
Pyrimidine salvage pathways in Toxoplasma gondii. J Eukaryot Microbiol (1993) 0.88
Genetic identification of essential indels and domains in carbamoyl phosphate synthetase II of Toxoplasma gondii. Int J Parasitol (2008) 0.87
Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase. Bioorg Med Chem Lett (2006) 0.87
An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int J Exp Pathol (1994) 0.85
Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans. FEBS J (2006) 0.85
The Toxoplasma gondii type-II NADH dehydrogenase TgNDH2-I is inhibited by 1-hydroxy-2-alkyl-4(1H)quinolones. Biochim Biophys Acta (2008) 0.85
Disruption of the proton relay network in the class 2 dihydroorotate dehydrogenase from Escherichia coli. Biochemistry (2009) 0.84
Plant dihydroorotate dehydrogenase differs significantly in substrate specificity and inhibition from the animal enzymes. FEBS Lett (2002) 0.84
Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria. Biochem Pharmacol (1998) 0.83
Enzymes of the de novo pyrimidine biosynthetic pathway in Toxoplasma gondii. Mol Biochem Parasitol (1983) 0.81
Resistance as a tool in the study of old and new drug targets in Toxoplasma. Drug Resist Updat (2001) 0.79
Cloning and expression of the dihydroorotate dehydrogenase from Toxoplasma gondii. Biochim Biophys Acta (2003) 0.78
Tagging of endogenous genes in a Toxoplasma gondii strain lacking Ku80. Eukaryot Cell (2009) 3.32
De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature (2002) 3.04
Phosphorylation of immunity-related GTPases by a Toxoplasma gondii-secreted kinase promotes macrophage survival and virulence. Cell Host Microbe (2010) 2.57
Efficient gene replacements in Toxoplasma gondii strains deficient for nonhomologous end joining. Eukaryot Cell (2009) 2.41
Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. EMBO J (2003) 2.26
K(ATP) channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J Physiol (2002) 2.18
Rapid membrane disruption by a perforin-like protein facilitates parasite exit from host cells. Science (2008) 2.15
Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS Pathog (2006) 2.08
Toxoplasma sortilin-like receptor regulates protein transport and is essential for apical secretory organelle biogenesis and host infection. Cell Host Microbe (2012) 1.78
A dynamin is required for the biogenesis of secretory organelles in Toxoplasma gondii. Curr Biol (2009) 1.77
A family of transmembrane microneme proteins of Toxoplasma gondii contain EGF-like domains and function as escorters. J Cell Sci (2002) 1.76
A novel family of Toxoplasma IMC proteins displays a hierarchical organization and functions in coordinating parasite division. PLoS Pathog (2010) 1.70
Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. PLoS Pathog (2011) 1.67
Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat Immunol (2003) 1.60
Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol (2006) 1.53
A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex. Mol Biol Cell (2006) 1.49
TLR adaptor MyD88 is essential for pathogen control during oral toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J Immunol (2008) 1.47
Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens. Mol Microbiol (2005) 1.45
Proteomic analysis of cleavage events reveals a dynamic two-step mechanism for proteolysis of a key parasite adhesive complex. Mol Cell Proteomics (2004) 1.44
The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem (2005) 1.40
Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. Eukaryot Cell (2011) 1.40
Toxoplasma gondii lacks the enzymes required for de novo arginine biosynthesis and arginine starvation triggers cyst formation. Int J Parasitol (2004) 1.39
Cathepsin L occupies a vacuolar compartment and is a protein maturase within the endo/exocytic system of Toxoplasma gondii. Mol Microbiol (2010) 1.36
Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J Immunol (2009) 1.28
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A (2012) 1.24
NK cells enhance dendritic cell response against parasite antigens via NKG2D pathway. J Immunol (2007) 1.16
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii. Infect Immun (2009) 1.10
A transient forward-targeting element for microneme-regulated secretion in Toxoplasma gondii. Biol Cell (2008) 1.09
Is Toxoplasma egress the first step in invasion? Trends Parasitol (2002) 1.09
Two separate, conserved acidic amino acid domains within the Toxoplasma gondii MIC2 cytoplasmic tail are required for parasite survival. J Biol Chem (2006) 1.08
Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun (2010) 1.08
An inside job: hacking into Janus kinase/signal transducer and activator of transcription signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect Immun (2011) 1.06
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res (2013) 1.06
Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. Antimicrob Agents Chemother (2006) 1.06
Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci (2004) 1.04
Cell cycle-dependent, intercellular transmission of Toxoplasma gondii is accompanied by marked changes in parasite gene expression. Mol Microbiol (2010) 1.03
Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res (2002) 1.03
Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment. Parasitol Int (2002) 1.02
Toxoplasma gondii cathepsin L is the primary target of the invasion-inhibitory compound morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl. J Biol Chem (2009) 1.02
Toxoplasma gondii protease TgSUB1 is required for cell surface processing of micronemal adhesive complexes and efficient adhesion of tachyzoites. Cell Microbiol (2010) 1.01
Functional analysis of Toxoplasma gondii protease inhibitor 1. J Biol Chem (2002) 0.99
Trans-genera reconstitution and complementation of an adhesion complex in Toxoplasma gondii. Cell Microbiol (2004) 0.98
Multimerization of the Toxoplasma gondii MIC2 integrin-like A-domain is required for binding to heparin and human cells. Mol Biochem Parasitol (2004) 0.98
New roles for perforins and proteases in apicomplexan egress. Cell Microbiol (2009) 0.96
Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. Proc Natl Acad Sci U S A (2006) 0.96
Cathepsin proteases in Toxoplasma gondii. Adv Exp Med Biol (2011) 0.96
Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. Infect Immun (2009) 0.93
Recent insights into apicomplexan parasite egress provide new views to a kill. Curr Opin Microbiol (2013) 0.92
RNG1 is a late marker of the apical polar ring in Toxoplasma gondii. Cytoskeleton (Hoboken) (2010) 0.92
Kinetic modeling of Toxoplasma gondii invasion. J Theor Biol (2007) 0.92
Non-canonical maturation of two papain-family proteases in Toxoplasma gondii. J Biol Chem (2012) 0.91
Targeted disruption of Toxoplasma gondii serine protease inhibitor 1 increases bradyzoite cyst formation in vitro and parasite tissue burden in mice. Infect Immun (2011) 0.91
The novel coccidian micronemal protein MIC11 undergoes proteolytic maturation by sequential cleavage to remove an internal propeptide. Int J Parasitol (2004) 0.90
Protein trafficking through the endosomal system prepares intracellular parasites for a home invasion. PLoS Pathog (2013) 0.89
Targeted deletion of MIC5 enhances trimming proteolysis of Toxoplasma invasion proteins. Eukaryot Cell (2006) 0.88
Forward targeting of Toxoplasma gondii proproteins to the micronemes involves conserved aliphatic amino acids. Traffic (2011) 0.87
Genetic identification of essential indels and domains in carbamoyl phosphate synthetase II of Toxoplasma gondii. Int J Parasitol (2008) 0.87
Functional dissection of Toxoplasma gondii perforin-like protein 1 reveals a dual domain mode of membrane binding for cytolysis and parasite egress. J Biol Chem (2013) 0.86
Mutation of an unusual mitochondrial targeting sequence of SODB2 produces multiple targeting fates in Toxoplasma gondii. J Cell Sci (2003) 0.86
Organisation and sequence determination of glutamine-dependent carbamoyl phosphate synthetase II in Toxoplasma gondii. Int J Parasitol (2003) 0.86
CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1. Infect Immun (2010) 0.86
A novel high throughput invasion screen identifies host actin regulators required for efficient cell entry by Toxoplasma gondii. PLoS One (2013) 0.86
Apicomplexan perforin-like proteins. Commun Integr Biol (2010) 0.85
Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans. FEBS J (2006) 0.85
Neospora caninum expresses an unusual single-domain Kazal protease inhibitor that is discharged into the parasitophorous vacuole. Int J Parasitol (2004) 0.85
Two different dihydroorotate dehydrogenases from yeast Saccharomyces kluyveri. FEBS Lett (2004) 0.85
Plant dihydroorotate dehydrogenase differs significantly in substrate specificity and inhibition from the animal enzymes. FEBS Lett (2002) 0.84
Dihydroorotate dehydrogenase from Saccharomyces cerevisiae: spectroscopic investigations with the recombinant enzyme throw light on catalytic properties and metabolism of fumarate analogues. FEMS Yeast Res (2007) 0.84
Toxoplasma gondii toxolysin 4 is an extensively processed putative metalloproteinase secreted from micronemes. Mol Biochem Parasitol (2011) 0.84
Genetic manipulation in Δku80 strains for functional genomic analysis of Toxoplasma gondii. J Vis Exp (2013) 0.84
Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion (2004) 0.83
MARveling at parasite invasion. Trends Parasitol (2008) 0.83
Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo. Appl Environ Microbiol (2007) 0.82
Identification and partial characterization of a second Kazal inhibitor in Toxoplasma gondii. Mol Biochem Parasitol (2003) 0.81
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol (2013) 0.81
A vacuolar-H(+) -pyrophosphatase (TgVP1) is required for microneme secretion, host cell invasion, and extracellular survival of Toxoplasma gondii. Mol Microbiol (2014) 0.80
Translocation of ribosomal protein P0 onto the Toxoplasma gondii tachyzoite surface. Int J Parasitol (2003) 0.80
Microneme protein 5 regulates the activity of Toxoplasma subtilisin 1 by mimicking a subtilisin prodomain. J Biol Chem (2012) 0.79
Toxoplasma gondii: generation of novel truncation mutations in the linker domain of dihydrofolate reductase-thymidylate synthase. Exp Parasitol (2004) 0.79